What are the treatment options for persistent hyponatremia?

Differential Diagnosis and Treatment of Persistent Hyponatremia

Diagnostic Algorithm for Persistent Hyponatremia

Begin by determining volume status through physical examination, though recognize this has limited accuracy (sensitivity 41.1%, specificity 80%). 1

Initial Laboratory Workup

• Obtain serum and urine osmolality, urine sodium, urine electrolytes, serum uric acid, and assess extracellular fluid volume status. 1
• Check serum creatinine, electrolytes (including potassium, calcium, magnesium), thyroid-stimulating hormone (TSH), and cortisol to rule out other causes. 1
• Serum glucose must be checked as hyperglycemia causes pseudohyponatremia—add 1.6 mEq/L to sodium for each 100 mg/dL glucose >100 mg/dL. 1

Volume Status Classification

Hypovolemic hyponatremia is characterized by orthostatic hypotension, dry mucous membranes, decreased skin turgor, flat neck veins, and urine sodium <30 mmol/L (71-100% positive predictive value for saline responsiveness). 1

Euvolemic hyponatremia shows no edema, no orthostatic hypotension, normal skin turgor, moist mucous membranes, urine sodium >20-40 mmol/L, and urine osmolality >300 mOsm/kg—this suggests SIADH. 1

Hypervolemic hyponatremia presents with peripheral edema, ascites, jugular venous distention, pulmonary congestion, and occurs in heart failure, cirrhosis, or renal disease. 1

Critical Distinction in Neurosurgical Patients

In patients with CNS pathology, distinguish SIADH from cerebral salt wasting (CSW) as treatments are opposite. 1

• SIADH: Normal to slightly elevated central venous pressure (CVP), euvolemic state, urine sodium >20-40 mmol/L, urine osmolality >500 mOsm/kg, serum uric acid <4 mg/dL (73-100% positive predictive value). 1
• CSW: Low CVP (<6 cm H₂O), true hypovolemia with hypotension and tachycardia, urine sodium >20 mmol/L despite volume depletion, more common in poor clinical grade and ruptured anterior communicating artery aneurysms. 1

---

Treatment Algorithm Based on Volume Status

Hypovolemic Hyponatremia

Administer isotonic saline (0.9% NaCl) for volume repletion at 15-20 mL/kg/h initially, then 4-14 mL/kg/h based on response. 1

• Discontinue diuretics immediately. 1
• For severe dehydration with neurological symptoms, consider hypertonic saline with careful monitoring. 1
• Avoid lactated Ringer's solution as it is hypotonic (130 mEq/L sodium, 273 mOsm/L) and can worsen hyponatremia. 1

Euvolemic Hyponatremia (SIADH)

Fluid restriction to 1 L/day is the cornerstone of treatment for mild to moderate asymptomatic SIADH. 1

• If no response to fluid restriction, add oral sodium chloride 100 mEq three times daily. 1
• For resistant cases, consider urea, demeclocycline, lithium, or loop diuretics. 1
• Tolvaptan 15 mg once daily may be considered for clinically significant hyponatremia resistant to fluid restriction, with careful monitoring to avoid overly rapid correction. 1, 2

Hypervolemic Hyponatremia (Heart Failure, Cirrhosis)

Implement fluid restriction to 1-1.5 L/day for serum sodium <125 mmol/L. 1

• Temporarily discontinue diuretics if sodium <125 mmol/L. 1
• In cirrhotic patients, consider albumin infusion (6-8 g per liter of ascites drained) alongside fluid restriction. 1
• Avoid hypertonic saline unless life-threatening symptoms are present, as it may worsen ascites and edema. 1
• Sodium restriction (2-2.5 g/day, 88-110 mmol/day) is more effective than fluid restriction for weight loss, as fluid passively follows sodium. 1
• Tolvaptan may be considered for persistent severe hyponatremia despite fluid restriction and maximization of guideline-directed medical therapy, but use with extreme caution in cirrhosis due to higher risk of gastrointestinal bleeding (10% vs 2% placebo). 1, 2

Cerebral Salt Wasting (Neurosurgical Patients)

Treatment focuses on volume and sodium replacement with isotonic or hypertonic saline—NOT fluid restriction. 1

• For severe symptoms, administer 3% hypertonic saline plus fludrocortisone (0.1-0.2 mg daily) in ICU setting. 1
• Aggressive volume resuscitation with normal saline 50-100 mL/kg/day or hypertonic saline for severe cases. 1
• Hydrocortisone may be used to prevent natriuresis in subarachnoid hemorrhage patients. 1
• Never use fluid restriction in CSW as this worsens outcomes. 1

---

Critical Correction Rate Guidelines

The maximum correction rate must not exceed 8 mmol/L in 24 hours to prevent osmotic demyelination syndrome. 1

Standard Correction Rates

• Average risk patients: 4-8 mmol/L per day, not exceeding 10-12 mmol/L in 24 hours. 1
• High-risk patients (advanced liver disease, alcoholism, malnutrition, prior encephalopathy): 4-6 mmol/L per day, maximum 8 mmol/L in 24 hours. 1

Severe Symptomatic Hyponatremia (Seizures, Coma, Altered Mental Status)

Administer 3% hypertonic saline immediately with target correction of 6 mmol/L over 6 hours or until severe symptoms resolve. 1

• Initial bolus: 100 mL over 10 minutes, can be repeated up to three times at 10-minute intervals until symptoms improve. 1
• Calculate sodium deficit: Desired increase in Na (mEq/L) × (0.5 × ideal body weight in kg). 1
• Monitor serum sodium every 2 hours during initial correction phase. 1
• Total correction must not exceed 8 mmol/L in 24 hours—if 6 mmol/L corrected in 6 hours, only 2 mmol/L additional correction allowed in next 18 hours. 1

Management of Overcorrection

If sodium correction exceeds 8 mmol/L in 24 hours, immediately discontinue current fluids and switch to D5W (5% dextrose in water). 1

• Consider administering desmopressin to slow or reverse the rapid rise in serum sodium. 1
• Watch for signs of osmotic demyelination syndrome (dysarthria, dysphagia, oculomotor dysfunction, quadriparesis) typically occurring 2-7 days after rapid correction. 1

---

Pharmacological Options for Persistent Hyponatremia

Vasopressin Receptor Antagonists (Vaptans)

Tolvaptan is FDA-approved for euvolemic or hypervolemic hyponatremia with serum sodium <125 mEq/L. 2

• Starting dose: 15 mg once daily, can titrate to 30 mg then 60 mg once daily based on response. 1, 2
• Contraindicated with strong CYP3A inhibitors (ketoconazole increases tolvaptan AUC 5.4-fold). 2
• Avoid with moderate CYP3A inhibitors and grapefruit juice. 2
• Monitor for thirst (12% vs 2% placebo), dry mouth (7% vs 2% placebo), polyuria (11% vs 3% placebo). 2
• In cirrhosis, tolvaptan carries higher risk of gastrointestinal bleeding (10% vs 2% placebo) and long-term use associated with increased all-cause mortality. 1, 2
• Avoid fluid restriction during first 24 hours of tolvaptan therapy to prevent overly rapid correction. 2

Alternative Pharmacological Agents

• Urea: Effective for SIADH, dose 40 g in 100-150 mL normal saline every 8 hours for 1-2 days. 1
• Demeclocycline: Reserved for persistent SIADH cases. 1
• Fludrocortisone: 0.1-0.2 mg daily for cerebral salt wasting, particularly in subarachnoid hemorrhage patients at risk of vasospasm. 1

---

Common Pitfalls to Avoid

Overly rapid correction of chronic hyponatremia exceeding 8 mmol/L in 24 hours causes osmotic demyelination syndrome. 1

Using fluid restriction in cerebral salt wasting worsens outcomes—CSW requires volume and sodium replacement. 1

Ignoring mild hyponatremia (130-135 mmol/L) as clinically insignificant—even mild hyponatremia increases fall risk (21% vs 5%) and mortality (60-fold increase with sodium <130 mmol/L). 1

Inadequate monitoring during active correction—check sodium every 2 hours for severe symptoms, every 4 hours after symptom resolution. 1

Failing to recognize and treat the underlying cause—identify medications (diuretics, antidepressants including trazodone), SIADH causes (malignancy, CNS disorders, pulmonary disease), or endocrine disorders. 1

Using hypertonic saline in hypervolemic hyponatremia without life-threatening symptoms—this worsens fluid overload. 1

Misdiagnosing volume status in heart failure patients—they may appear dehydrated but have underlying hypervolemic hyponatremia requiring fluid restriction, not saline. 1